When Janet Freeman-Daily, a former aerospace engineer and self proclaimed “science geek,” was diagnosed with lung cancer, she made it her mission to learn about her disease.
Her curious nature eventually led her down the path of cutting-edge treatment — she was one of the early patients tested for a rare ROS1 mutation, and secured a spot in a clinical trial for a targeted therapeutic. Her cancer has been controlled with crizotinib ever since, and she founded the nonprofit The ROS1ders to help other patients.
